<- Go Home
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Market Cap
ILS 8.6M
Volume
2.1M
Cash and Equivalents
ILS 150.0K
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-ILS 2.3M
Profit Margin
232.85%
52 Week High
ILS 0.04
52 Week Low
ILS 0.01
Dividend
N/A
Price / Book Value
-170.92
Price / Earnings
-1.06
Price / Tangible Book Value
-170.92
Enterprise Value
ILS 8.4M
Enterprise Value / EBITDA
N/A
Operating Income
-ILS 6.0M
Return on Equity
577.13%
Return on Assets
-240.56
Cash and Short Term Investments
ILS 259.0K
Debt
ILS 86.0K
Equity
-ILS 47.0K
Revenue
ILS 968.0K
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium